CKPT stock icon

Checkpoint Therapeutics
CKPT

$1.94
4.35%
 

About: Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

Employees: 23

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 3 analysts
0
News positive %
of 22 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

2.18% more ownership

Funds ownership: 21.4% [Q4 2023] → 23.58% (+2.18%) [Q1 2024]

2% more call options, than puts

Call options by funds: $826K | Put options by funds: $809K

0% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 12

1% less capital invested

Capital invested by funds: $11.2M [Q4 2023] → $11M (-$166K) [Q1 2024]

9% less funds holding

Funds holding: 43 [Q4 2023] → 39 (-4) [Q1 2024]

36% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 11

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$4
106%
upside
Avg. target
$24
1,137%
upside
High target
$34
1,653%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Joseph Pantginis
1,653%upside
$34
Buy
Reiterated
16 May 2024
HC Wainwright & Co.
Joseph Pantginis
1,653%upside
$34
Buy
Reiterated
22 Mar 2024
B. Riley Securities
Mayank Mamtani
106%upside
$4
Buy
Maintained
20 Dec 2023

Financial journalist opinion

Based on 22 articles about CKPT published over the past 30 days